Keep updated with the latest MDPP news via our newsletter.
TTRA for Diabetes and Cardiovascular Disease Announces TTRA for Diabetes and Cardiovascular Disease Announces Research Plans and Partners
MTPConnect’s Targeted Translation Research Accelerator (TTRA) initiative for diabetes and MTPConnect’s Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease (D&CVD) will soon call for expressions of interest to establish two Research Centres and open the first round of Research Project funding.
The $47 million TTRA initiative, supported by the Medical Research Future Fund (MRFF), is providing a new integrated research program to improve the prevention, management and treatment of diabetes and cardiovascular disease (D&CVD) in Australia. Research efforts will focus on the most pressing areas of unmet clinical and research needs in D&CVD, which are leading causes of death and disability in Australia.
The TTRA program is designed to support and incentivise translation as a natural course of activity for those applying and receiving funding.
MTPConnect is pleased to announce partnerships with ANDHealth, Medical Device PartneringProgram (MDPP) and UniQuest to provide advice and mentoring for funding recipients.
MTPConnect Managing Director & CEO, Dr Dan Grant, has welcomed the TTRA partners, citing their credentials as preeminent organisations specialising in translation and commercialisation of digital health, medical technology, medical devices, biotechnology and pharmaceuticals.
“We are delighted to announce our partnerships with ANDHealth, MDPP and UniQuest for the TTRA as we embark on a mission to improve the prevention, diagnosis, treatment and management of diabetes and cardiovascular disease in Australia,” Dr Grant said.
“Our experience leading a number of Medical Research Future Fund programs has proven the value of building in a component for guidance and support for research applicants,” he said.
UniQuest is Australia’s leading technology transfer company, whose innovation portfolio includes Australia’s first blockbuster vaccine Gardasil®. UniQuest’s Executive Director of Commercialisation, Dr Mark Ashton says bringing commercialisation experience to early stage research will transform ideas to impact.
”We are looking forward to drawing on the industry expertise of our team at the Queensland Emory Drug Discovery Initiative (QEDDI) and our 35 years’ experience in commercialisation to support applicants in the translation of their research, with the view to improving the outlook for patients with diabetes and cardiovascular disease around the world,” Dr Ashton said.
MDPP Executive Director, Professor Karen Reynolds leads the ideas incubator to support the development of novel medical devices and assistive technologies.
“MDPP is honoured to once again partner with MTPConnect and support the development of novel preventive, diagnostic and therapeutic approaches and products to improve outcomes for diabetes and cardiovascular disease. With the rapid changes within the community, health and business environments, the TTRA will provide a strategic and coordinated effort to translate cutting-edge research to knowledge for two disease states that affect millions of Australians each year,” Professor Karen Reynolds said.
The Medical Device Partnering Program (MDPP) Ideas Incubator is a proven tool for developing world-class medical devices and helping innovators in their first steps through research, clinical and industry partnerships.
Learn more about what the MDPP does and how you can be a part of it, by joining the free Building Healthcare Innovations with the Medical Device Partnering Program webinar
Sorry you missed the webinar but you can watch the recording here. Passcode 7gQ.M4u^
New directory connecting Australia’s medical device sector launched to drive innovation
The Medical Device Partnering Program today launches the first dedicated online Capability Directory for the medical device sector, to boost innovation and development of cutting-edge medical devices and technologies in Australia.
Funded by MTPConnect, the Capability Directory incorporates details of more than 2,600 Australian organisations relevant to the medical device industry, bringing together expert research, clinical and manufacturing capabilities of Australian organisations.
The directory will help innovators to connect with organisations so they can develop their idea ready for market. It can be used by businesses to identify research organisations who can help to develop new products, or by start-up enterprises looking for advanced manufacturers who can build new products.
The MDPP is an ideas incubator, fostering collaborations between researchers, industry, end-users and government to develop new medical devices and technologies with global market potential. Led by Professor Karen Reynolds of Flinders University, the Program provides a mechanism to develop proof of concept, prototyping, clinical evaluation and commercialisation planning.
“Our aim is to build on the current research and manufacturing capability across the nation and develop Australia’s position as a global leader in the growing medical devices market. Our new Capability Directory is going to make it a lot easier for innovators to tap into the rich sovereign ecosystem that exists here and get the support they need to develop, commercialise and locally manufacture a new medical device,” said MDPP Director Professor Karen Reynolds.
“As we move into a new era of adaptation and flexibility, driven by extraordinary challenges such as the COVID-19 pandemic, manufacturers can pivot into new markets when given the opportunity and connections to do so and our Capability Directory can help.
“We experienced this firsthand when setting up a PPE testing facility with UniSA to support COVID-19 face mask testing facility for Australia. The connections to experts in materials science, medical device research, clinical validation and therapeutic product regulation in the directory made it possible to do so rapidly” said Professor Reynolds.
MTPConnect Managing Director and CEO, Dr Dan Grant, explained the Directory had been commissioned because there was a need for a central repository of stakeholders in the medical technology sector.
“We need to integrate and connect the expertise we have across our nation to promote industry growth, and the MDPP’s Capability Directory represents a valuable resource for the medical innovation community who are creating high-tech medical devices to improve health and wellbeing,” said Dr Dan Grant.
The MDPP has been named a finalist in the Excellence in Science and Industry Collaboration section of the South Australian Science Excellence Awards, for the work it does with inventors from research, industry and clinical settings by facilitating the design, patenting and development of new medical technologies and products - including the ‘Ezy-Aim’ orthopaedic surgery device by Austofix and Ferronova’s early stage cancer diagnostics device.
The Capability Directory is now online at the MDPP website: https://mdpp.org.au/capability
We are hiring!
We are looking for an Innovations Officer (MDPP) to join our South Australian team based at Flinders University. The Innovations Officer (MDPP) will support the Innovations Manager (MDPP) in managing client liaison, assessing viability of proposals and preparing detailed commercial reports for the Medical Device Partnering Program (MDPP). The position will work alongside like-minded colleagues committed to growing Australia's medtech sector, who value innovation and have exceptional capabilities in research, commercialisation and partnership.
Applications close Thursday 17th September at 11am ACST.
For more information and to apply visit - https://jobs.flinders.edu.au/en/job/497414/innovations-officer
Update on MDPP Victoria by Oded Van Ham, Operations Manager, MDPP Victoria.
MDPP Victoria, supported by LaunchVic, have approved and funded a total of 13 projects since the start of 2019. We are supporting start-ups and existing companies by connecting them with Victoria’s research and development community across hospitals, universities and industry partners. It is exciting to see that our work is also enabling our clients to attract substantial additional funding (see Lenexa Medical secures $650,000 Accelerating Commercialisation grant).
The MDPP Victoria team are thrilled to announce we completed hand over for our first projects to clients (four by end of July). In all cases working device prototypes have been collaboratively developed and tested for the client. At the same time the MDPP team provides commercial assessment reports with additional insights into a specific market opportunity for these devices. The newly completed projects include
More details will be publicised for these and other projects soon.
Melbourne, Australia - 26 June 2020: Melbourne-based technology company, Lenexa Medical, have been successful in their application for a highly competitive $650,000 Accelerating Commercialisation grant.
Having recently collaborated with the Victorian Medical Device Partnering Program (MDPP) team, which is supported by LaunchVic, Lenexa Medical are developing innovative technology for pressure injury (PI) risk management and patient monitoring. The device, an ultra-thin sheet with sensor technology, provides real-time ongoing monitoring for PI risk.
“Engaging with the MDPP has no doubt contributed to our grant success. Through the MDPP’s network of experts, they were able to objectively evaluate our product offering, guide our proof of concept development and help to further refine our clinical strategy. The success of our grant application was helped greatly with this clear direction and guidance.” said Lenexa Medical’s Co-Founder and Chief Scientific Officer, Will Yang.
The new round of funding for the $22.3 million Biomedical Translation Bridge (BTB) program is now open.
The third round of the BTB program (COVID-19 Response) is open from Monday 18 May to Monday 1 June 2020.
In this specific COVID-19 call, the BTB Program can provide up to $1million to support eligible organisations develop medical devices, diagnostics, prophylactic or therapeutic approaches that will achieve an impact on the global response to the pandemic in less than 12 months.
Funding will support Australian small and medium enterprises, medical research institutes and universerities conducting COVID-19 related research projects.
Applicants will be required to provide one-to-one matching funding in the form of cash to be eligible.
For full details of the guidelines and application process visit the MTPConnect website.
MTPConnect is delivering the BTB program in partnership with BioCurate (Melbourne and Monash Universities), UniQuest (University of Queensland), the Medical Device Partnering Program (led by Flinders University) and the Bridge and BridgeTech programs (Queensland University of Technology).